Tissuemed has announced the publication of a first clinical paper* by neurosurgeons at the University of Padova, Italy detailing the use of TissuePatchDural in a small patient cohort undergoing surgery with a high risk of CSF leakage. During the course of this 12 patient series, the authors, Alessandro Della Puppa, Marta Rossetto and Renato Scienza only used TissuePatchDural when a water tight closure of the dura had not been achieved through traditional closure means. Clinical and neuro-radiological follow-up varied from 5 to 9 months. There was no evidence of CSF leak in any patient and no device related adverse events occurred.
Dr Della Puppa explains, “TissuePatchDural is a sealant, like biological glues, but unlike them it is a large film able to cover large dural surfaces affected by multiple defects. Moreover, the application does not take time to be prepared, as with biological glues…In our current dural defect management in selected patients the use of TissuePatchDural has reduced time of repairing and improved final results”.
Dr David Mandley, Tissuemed’s director responsible for Clinical affairs commented, “This surgeon led initiative from the team in Padova, provides an excellent demonstration of the effectiveness, ease of use and safety of TissuePatchDural as an dural sealant. I expect this paper to be the first in a series of publications describing the clinical use of this novel surgical sealant film. Furthermore, this publication is applicable to ObexNeuroFilm, an equivalent product that from 1st September is being distributed exclusively by our partners at Medtronic.
*British Journal of Neurosurgery, October 2010; 24(5): 609–611. Reprints available on request. Please email email@example.com